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(57) ABSTRACT
The present technology is directed to methods of soft tissue
emulsification using a mechanism of ultrasonic atomization
inside gas or vapor cavities, and associated systems and
devices. In several embodiments, for example, a method of
non-invasively treating tissue includes pulsing ultrasound
energy from the ultrasound source toward the target site in
tissue. The ultrasound source is configured to emit high
intensity focused ultrasound (HIFU) waves. The target site
comprises a pressure-release interface of a gas or vapor
cavity located within the tissue. The method continues by
generating shock waves in the tissue to induce a lesion in the
tissue at the target site. The method additionally includes
characterizing the lesion based on a degree of at least one of
a mechanical or thermal ablation of the tissue.
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METHODS OF SOFT TISSUE
EMULSIFICATION USING A MECHANISM
OF ULTRASONIC ATOMIZATION INSIDE
GAS OR VAPOR CAVITIES AND
ASSOCIATED SYSTEMS AND DEVICES
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claims the benefit of U.S. Provisional
Application No. 61/474,080, filed Apr. 11, 2011, and U.S.
Provisional Application No. 61/488,552, filed May 20, 2011,
both of which are incorporated herein by reference in their
entireties.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH
This invention was made with government support under
1ROIEB007643-01A2 awarded by National Institutes of
Health (NIH) and SMST01601 (NASA NCC 9-58) awarded
by National Space Biomedical Research Institute (NSBRI).
The government has certain rights in the invention.
TECHNICAL FIELD
The present technology relates generally to high intensity
focused ultrasound. In particular, several embodiments are
directed toward methods and systems for non-invasive treat-
ment of tissue using high intensity focused ultrasound
therapy.
BACKGROUND
Minimally invasive and non-invasive therapeutic ultra-
sound treatments can be used to ablate, necrotize, and/or
otherwise damage tissue. High intensity focused ultrasound
("HIFU"), for example, is used to thermally or mechanically
damage tissue. HIFU thermal treatments increase the tem-
perature of tissue at a focal region such that the tissue
quickly forms a thermally coagulated treatment volume.
HIFU treatments can also cause mechanical disruption of
tissue with well-demarcated regions of mechanically emul-
sified treatment volumes that have little remaining cellular
integrity. For certain medical applications, tissue emulsifi-
cation may be more favorable than thermal damage because
it produces liquefied volumes that can be more easily
removed or absorbed by the body than thermally coagulated
solid volumes.
HIFU treatments can utilize a sequence of pulses, rather
than continuous-wave HIFU exposures, to reduce undesir-
able thermal effects on the surrounding tissue. In histotripsy
exposures, for example, HIFU sources operate with low duty
cycles (e.g., 1%), use relatively short pulses (e.g., 10-20
microseconds), and deliver high pulse average intensities of
up to 40 kW/cm2 to form bubbles that mechanically disrupt
tissue. Histotripsy techniques, for example, can induce cavi-
tation by delivering pulses of high peak negative pressures
that are significantly higher than the tensile strength of the
tissue. The repetition of such pulses can increase the area of
tissue affected by cavitation to create a "cavitation cloud"
that emulsifies the tissue. Cavitation, however, is generally
stochastic in nature, making cavitation-based HIFU treat-
ments somewhat unpredictable and difficult to reproduce.
Therefore, there is a need to enhance the reliability, predict-
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ability, and repeatability of mechanical disruption of tissue
damage (e.g., emulsification).
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic view of a HIFU system configured
in accordance with an embodiment of the present technol-
ogy.
FIGS. 2A-2C are illustrations of planar ultrasound waves
to modeled at a pressure-release interface in tissue in accor-
dance with several embodiments of the present technology.
FIGS. 3A-3C are illustrations of focal ultrasound waves
modeled at a pressure-release interface in tissue in accor-
dance with several embodiments of the present technology.
15 FIG. 3D is a set of photographs of focal ultrasound waves
applied to a pressure-release interface in tissue in accor-
dance with several embodiments of the present technology.
FIGS. 4A-4D are photographs of various types of lesions
formed in tissue using HIFU in accordance with embodi-
20 ments of the present technology.
FIG. 5 is a block diagram illustrating a method of treating
tissue at a target site in accordance with an embodiment of
the present technology.
25 DETAILED DESCRIPTION
The present technology is directed to methods of soft
tissue emulsification using a mechanism of ultrasonic atomi-
zation inside gas or vapor cavities, and associated systems
3o and devices. In several embodiments, for example, a method
of non-invasively treating tissue includes pulsing ultrasound
energy from the ultrasound source toward the target site in
tissue. The ultrasound source is configured to emit HIFU
waves. The target site comprises a pressure-release interface
35 of a gas or vapor cavity located within the tissue. The
method continues by generating shock waves in the tissue to
induce a lesion in the tissue at the target site. The method
additionally includes characterizing the lesion based on a
degree of at least one of a mechanical or thermal ablation of
40 the tissue. These HIFU systems and methods have a number
of both therapeutic and cosmetic applications, such as pro-
ducing bulk ablation of benign and malignant tumors.
Certain specific details are set forth in the following
description and in FIGS. 1-5 to provide a thorough under-
45 standing of various embodiments of the technology. For
example, several embodiments of HIFU treatments that
destroy tissue are described in detail below. The present
technology, however, may be used to destroy multi-cell
structures similar to tissue. Additionally, the term "target
50 site" is used broadly throughout the disclosure to refer to any
volume or region of tissue that may benefit from HIFU
treatment. Other details describing well-known structures
and systems often associated with ultrasound systems and
associated devices have not been set forth in the following
55 disclosure to avoid unnecessarily obscuring the description
of the various embodiments of the technology. A person of
ordinary skill in the art, therefore, will accordingly under-
stand that the technology may have other embodiments with
additional elements, or the technology may have other
60 embodiments without several of the features shown and
described below with reference to FIGS. 1-5.
FIG. 1 is a schematic view of a HIFU system 100
configured in accordance with an embodiment of the present
technology. The HIFU system 100 can include a HIFU
65 source 102 operably coupled to a function generator 104 and
an amplifier 106. The HIFU source 102 can be an ultrasound
transducer that emits high levels of ultrasound energy to a
US 9,498,651 B2
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focus 120. The focus 120 can be a point, plane, or region at
which the intensity from the HIFU source 102 is the highest.
In other embodiments, the HIFU source 102 can include a
single-element device, a multi-element device, an extracor-
poreal device, an intracavitary device, and/or other devices 5
or systems configured to emit HIFU energy to a focus. The
HIFU source 102 can have a frequency range of approxi-
mately 0.5-20 MHz. In other embodiments, the frequency of
the HIFU source 102 can vary. The function generator 104
(e.g., an Agilent 33250A function generator from Agilent of io
Palo Alto, Calif.) and the amplifier 106 (e.g., an ENI A-300
300 W RF amplifier from ENI of Rochester, N.Y.) can drive
the HIFU source 102 to generate pulsed shock waves
proximate to the focus 120. Accordingly, the HIFU system
100 can implement a pulsing protocol in which ultrasound 15
frequency, pulse repetition frequency, pulse length, duty
cycle, pressure amplitude, and/or other factors associated
with the HIFU treatment can be adjusted to generate shock
waves proximate to the focus 120.
During treatment the HIFU source 102 can be positioned 20
proximate to tissue 108, and the focus 120 of the HIFU
source 102 can be aligned with at least a portion of a target
site 122 within the tissue 108. For example, the HIFU source
102 can be positioned over a patient's kidney, heart, or liver,
and the focus 120 can be aligned with infected or otherwise 25
adverse tissue therein. In still other embodiments, a variety
of other types of tissue may be treated using the HIFU
system 100. Larger target sites 122 can be mechanically
fractionated by scanning the HIFU source 102 over the
treatment region using either mechanical or electronic scan- 30
ning. Such scanning and the initial positioning of the HIFU
source 102 can be performed manually or mechanically
(e.g., using a three-axis positioning system, not shown). The
function generator 104 can initiate the pulsing protocol to
generate shock waves with amplitudes between approxi- 35
mately 10 MPa and approximately 80 MPa at the focus 120
with the HIFU source 102 having a frequency of approxi-
mately 2 MHz. In other embodiments, such as at lower or
higher ultrasound frequencies, the shock wave amplitudes of
the HIFU source 102 can be greater or smaller. Absorption 40
of ultrasonic energy occurs primarily at the shock front and
induces heating of the tissue 108 that can exceed boiling
temperature in the tissue 108.
During each HIFU pulse, one or more boiling bubbles can
be formed in the tissue. In several embodiments, for 45
example, the boiling bubbles can have cross-sectional
dimensions of approximately 2-4 mm when the ultrasound
frequency is approximately 2 MHz. In other embodiments,
however, the boiling bubbles can be larger or smaller. For
example, the boiling bubbles in the tissue can have a 50
cross-sectional dimension between approximately 100 µm
and approximately 4 mm on the order of the beam-width of
the ultrasound source 102 at the focus 120. The superheated
vapor of the boiling bubbles provides a force pushing
outward from the bubble. This repetitive explosive boiling 55
activity and interaction of the ultrasound shock waves with
the boiling bubbles emulsifies the tissue 108 at the target site
122 to form a liquid-filled lesion, at least partially devoid of
cellular structure, with little to no thermal coagulation
within the treated region. The reflection of the shock wave 60
from the surface of these millimeter-sized boiling bubbles
can also form cavitation bubbles proximate to the boiling
bubble that can also induce mechanical damage to tissue.
Mechanical tissue destruction can occur consistently
within localized treatment volumes when the temperature of 65
the tissue reaches 100° C. and boiling bubbles form during
each pulse or after a series of consecutive pulses. For
_►,
example, boiling bubbles are generally produced proximate
to the focus 120 of the HIFU source 102 (i.e., where shock
wave amplitude is the highest). Alternatively, cavitation
bubbles can be induced randomly over a larger region. In
selected embodiments, for example, the energy deposition of
the ultrasound beam can focus within 100 microns of the
target site 122. In other embodiments, however, this distance
may vary.
In selected embodiments, the pulsing protocol of the
HIFU system 100 can be adjusted to control the type of
lesion formed in the tissue (e.g., a "liquid" lesion a com-
pletely liquefied mechanical lesion; a "paste" lesion —a
partially denatured mechanical lesion; a "thermal" lesion —a
thermal lesion with no mechanical damage; or a "boiling"
lesion a thermally denatured lesion with mechanical dam-
age). For example, repeating 10 ms duration shock waves at
a pulse repetition frequency that is slow enough (e.g.,
approximately 2 MHz or 1% duty cycle) to allow cooling
between the pulses such that lesion content within the target
site 122 and the surrounding tissue 108 shows minimal to no
evidence of thermal denaturation. A duty cycle of less than
approximately 10% also allows cooling between pulses that
minimizes thermal denaturation. In selected embodiments,
the duration of the pulses can be reduced over the course of
the pulsing protocol to account for a decreasing time to boil
caused by the retention of heat in the tissue 108 between
pulses. Additionally, the duration of each pulse can be such
that the thermally denatured volume of the tissue 108 within
each pulse is negligible. For example, in selected embodi-
ments, the duration of each pulse is less than approximately
10 ms. In other embodiments, however, the pulse length can
be longer.
In several embodiments, the target site 122 comprises a
pressure-release interface within the tissue 108. For
example, the target site 122 can include tissue 108 adjacent
to an inherent or induced gas or vapor cavity. The gas or
vapor cavity can be natural, e.g., gas pockets in the lungs or
intestine. Alternately, the bubbles can be created in the tissue
108 by other physical means, including laser ablation or
vaporization droplets, e.g., liposomes injected in the vascu-
lar system by mild heating. The bubbles can also be intro-
duced by HIFU in the form of cavitation or boiling bubbles
in the soft tissue. For example, as discussed above, HIFU
has been shown to extracoporeally emulsify regions of bulk
tissue by shock wave heating and millisecond boiling,
creating bubbles or cavitation bubble clouds. As will be
discussed in further detail below with reference to FIGS.
2A-3D, the bubbles or bubble clouds are large enough to act
as a pressure-release interface, allowing acoustic atomiza-
tion and fractioning the tissue into submicron-sized frag-
ments.
The HIFU system 100 can also include systems or devices
that detect and monitor tissue ablation initiation and the
activity (e.g., heating or bubble activity) in the tissue 108. In
some embodiments, for example, these devices can be used
during treatment to distinguish boiling bubbles from cavi-
tation bubbles and ensure the pulsing protocol is set to
parameters that will induce the desired lesion type. In the
embodiment illustrated in FIG. 1, for example, the HIFU
source 102 is operably coupled to a voltage probe 110 and
an oscilloscope 112 that can monitor and record, respec-
tively, the drive voltage at the HIFU source 102. In other
embodiments, however, the HIFU source 102 may be
coupled to additional detection and/or monitoring devices.
The HIFU system 100 can also include a passive cavita-
tion detector ("PCD") 124 that monitors acoustic signals
associated with tissue ablation. For example, the PCD 124
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can include an acoustic receiver (e.g., an ultrasound trans-
ducer) separate from the HIFU source 102, but confocally
aligned with the focus 120 of the HIFU source 102 such that
the PCD 124 can receive real-time acoustic feedback during
HIFU treatment. In general, boiling bubbles scatter frequen- 5
cies that already exist in the incident wave, whereas cavi-
tation bubbles create short pops when they collapse and have
a broadband frequency noise. Boiling bubbles may also
generate lower frequency noise (e.g., kilohertz frequencies)
that can be recorded and used to monitor treatments. As 10
shown in FIG. 1, similar to the voltage probe 110, the PCD
124 can also be coupled to the oscilloscope 112 to record
acoustic signals during HIFU treatment.
Echogenic ablation activity and/or the thermal effects of
the HIFU treatment can also be monitored using separate 15
devices and systems. The HIFU system 100 illustrated in
FIG. 1, for example, includes an imaging system 114 that
can create a visual image to monitor the boiling bubbles and
thus temperatures of approximately 100° C. in real-time at
a depth within the tissue 108. The imaging system 114 can 20
be a separate confocal transducer, an unfocused transducer,
another type of confocal or unfocused ultrasound source,
one or more sub-element(s) of a multi-element array, and/or
a separate imaging system. For example, in one embodiment
the imaging system 114 includes an HDI-1000 scanner with 25
a CL 10-5 scanhead made by Philips Medical Systems of
Bothell, Wash. In other embodiments, the imaging system
114 can include a magnetic resonance imaging ("MRI")
system that can monitor temperature and boiling activity
during HIFU treatments or other suitable devices. 30
In the embodiment shown in FIG. 1, the HIFU system 100
also includes a high-speed camera 116 (e.g., video, still
frame) to take video or still images of the target site 122
during HIFU treatment to capture the effects of the HIFU
treatment on the tissue 108. Such a camera 116 is generally 35
used with initially transparent tissues or tissue phantoms to
capture the thermal effects of HIFU treatment within the
tissue 108. Accordingly, the high-speed camera 116 can be
especially suited for experiments and testing that include
transparent gel phantoms to simulate tissue. The high-speed 40
camera 116 is an optional component that may not be used
in some embodiments.
The HIFU system 100 can also simulate the shock waves
and heating in water or tissue. Resultant modeling can be
used to calculate heating from the shock amplitude of the 45
focal waveform, and for extrapolating pressure waveforms
at the focus 120 in water to the equivalent waveforms in
tissue. One such method for this extrapolation is called
"derating," and is useful for regulatory oversight and HIFU
treatment planning. For example, derating can be used to 50
determine values of the acoustic field parameters in the
tissue region exposed to HIFU (e.g., the target site 122 and
the surrounding tissue 108). During the derating process,
low level ultrasound measurements can be taken at the focus
120 in water and scaled to the higher level outputs used 55
during therapeutic HIFU treatments.
The HIFU system 100 can also include a testing apparatus
130 that can assess the extent of mechanical and/or thermal
ablation and distinguish among lesion types. In some
embodiments, for example, the testing apparatus 130 can 60
send feedback to the function generator 104 or other com-
ponents of the HIFU system 100 to cause the function
generator 104 to select ultrasound parameters designed to
achieve a particular type of mechanical or thermal ablation.
For example, as will be discussed in further detail below 65
with reference to FIGS. 4A-4D, a user may desire to create
a lesion that can be categorized as one of a liquid lesion, a
T
paste lesion, a boiling lesion, or a thermal lesion. The testing
apparatus 130 can determine the type of lesion created by the
ultrasound source 102 and then automatically instruct the
function generator 104 to alter or fine-tune HIFU parameters
to better achieve the characteristics of the desired lesion. In
further embodiments, the testing apparatus 130 may supply
information to a user to allow the user to manually adjust
HIFU settings as necessary to achieve the desired lesion
type. As will be discussed in further detail below, the testing
apparatus 130 can characterize or distinguish ablated tissue
at the target site 122 according to at least one of a histo-
logical or biochemical trait.
Further details regarding HIFU system components and
operating parameters can be found in U.S. patent application
Ser. No. 13/085,368, filed Apr. 12, 2011 and entitled "Meth-
ods and Systems for Non-Invasive Treatment of Tissue
Using High Intensity Focused Ultrasound Therapy," which
is hereby incorporated by reference in its entirety.
FIGS. 2A-3D illustrate various steps of atomizing tissue
at pressure-release interfaces using a suitable HIFU system
(e.g., the HIFU system 100 of FIG. 1). The techniques for
atomizing tissue described below, for example, are directed
to particular applications of the HIFU system and associated
methods described above. FIGS. 2A-2C, for example, are
sequential illustrations of planar waveforms modeled at a
pressure-release interface 250 between tissue 252 and a gas
or vapor cavity 262 in accordance with several embodiments
of the present technology.
FIG. 2A illustrates the pressure-release interface 250 after
the initial application of planar shock waves P. FIG. 2B
illustrates the pressure-release interface 250 when capillary
waves 254 have been parametrically excited on a surface
256 of the tissue 252. In some embodiments, the capillary
waves 254 are excited at half of the ultrasound frequency.
FIG. 2C illustrates the pressure-release interface 250 after
cavitation and instability of sharp cusps of the capillary
waves 254 have caused the emission of droplets or atomi-
zation 264 in the tissue 252.
FIGS. 3A-3C are sequential illustrations of focal wave-
forms modeled at a pressure-release interface 350 between
tissue 352 and a gas or vapor cavity 362 in accordance with
several embodiments of the present technology. FIG. 3A, for
example, illustrates the pressure-release interface 350 upon
initial application of focused shock waves F. The radiation
force from the shock waves F causes a surface 356 of the
tissue 352 to become concave at a focal point 358 of the
radiation. FIG. 3B illustrates the pressure-release interface
350 after cavitation bubbles 360 have appeared under the
surface 356 of the tissue 352. FIG. 3C illustrates the pres-
sure-release interface 350 after cavitation and capillary
waves have caused an acoustic fountain and atomization 366
of the tissue 352. The gas or vapor cavity 362 provides the
space for the tissue 352 to excite and atomize in this manner.
FIG. 3D is a set of photographs of focal ultrasound waves
applied to a pressure-release interface in tissue in accor-
dance with several embodiments of the present technology.
Referring to FIGS. 3A-3D together, in some embodi-
ments, the projectiles atomizing from the acoustic fountain
366 can include both fragmented and whole cells and nuclei.
In some embodiments, the water content of the tissue 352
can contribute to the degree of tissue erosion. For example,
the water content of the tissue 352 can decrease the tissue
stiffness and/or the tissue cavitation threshold, thereby
increasing the ease of emulsification. Further, water may
contribute to tissue emulsification by forming a slurry that is
recirculated within the boiling bubble or cavitation bubble
cloud. Accordingly, a portion of the tissue 352 can be wetted
US 9,498,651 B2
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(e.g., misted with water or a saline solution) prior, during, or
after a HIFU treatment. Many types of tissue can exhibit this
acoustic fountain effect, including, for example, kidneys,
esophageal tissue, skeletal muscle, blood clots, spleen tissue,
and/or other suitable tissue. 5
FIGS. 4A-4D are photos of various types of lesions
formed in tissue using HIFU in accordance with embodi-
ments of the present technology. The photos are arranged in
order of decreasing liquid and increasing thermal compo-
nents. For example, FIG. 4A illustrates a "liquid" lesion 410, 1 o
FIG. 4B illustrates a "paste" lesion 420, FIG. 4C illustrates
a "boiling" lesion 430, and FIG. 4D illustrates a "thermal'
lesion 440. FIGS. 4A, 413, and 4D include dashed lines to
more clearly delineate the ablated and unscathed tissue. For
purposes of this disclosure, a liquid lesion 410 is one in 15
which the tissue is nearly or completely emulsified. The
lesion 410 includes only mechanical ablation, and no ther-
mal effects. As shown in FIG. 4A, the lesion 410 includes
active enzymes in the ablated region. For purposes of this
disclosure, a paste lesion 420 can be considered slightly 20
more viscous than a liquid lesion 410, with some non-active
enzymes remaining in the lesion 420. For purposes of this
disclosure, a boiling lesion 430 includes some pieces of
non-emulsified tissue, while a thermal lesion 440 has been
at least partially ablated by heat, with a blurrier boundary 25
line between treated and untreated tissue.
A testing method or apparatus, such as testing apparatus
130 described above with reference to FIG. 1, can be used
to distinguish among the various types of lesions. In some
embodiments, for example, a lesion can be analyzed for 30
microscopic anatomical/structural changes or changes in the
quantity or type of cells, molecules, or cellular components.
In further embodiments, the testing apparatus can perform
biochemical analyses of samples at or around a target site. In
some embodiments, a frozen embed of the treatment site can 35
be sectioned and stained to determine cellular structure or
contents. In particular embodiments, Haeomatoxylin and
Eosin stain and/or nicotinamide adenine dinucleotide dia-
phorase stain are used to better view changes to the general
tissue structure and effects of thermal treatment, respec- 40
tively. In other embodiments, however, other suitable tech-
niques may be used to test/analyze the treated tissue.
In still further embodiments, the extent of thermal abla-
tion in a lesion can be determined by analyzing the quantity
of protein in a lesion sample, as heated proteins denature and 45
become less soluble in water. The contents of the lesion can
be removed and a serial salt extraction applied. A Bradford
assay or other suitable test can quantify proteins in the
sample. In some embodiments, for example, the lesion is
characterized as liquid if there is no denatured protein 50
relative to a control sample; as paste if there is approxi-
mately 20%-40% denatured protein relative to the control;
as boiling if there is approximately 80-85% denatured
protein relative to the control; and as thermal if there is
approximately 85% or more denatured protein relative to the 55
control. Liquid lesions are purely mechanical lesions, and
therefore have not suffered from thermally-induced protein
denaturation. In further embodiments, a spectrophotometric
determination can distinguish among lesion types.
As discussed above, a HIFU system can be configured to 60
implement pulsing parameters that correspond to a particu-
lar, desired type of lesion. The feedback based on the lesion
characterization can be used to modify ultrasound param-
eters. Referring to general histological trends, an increased
pulse length, duty cycle, or thermal component will create a 65
more thermal, less liquid lesion (and vice versa) while
increasing structural disruption of the tissue will create a
8
more liquid, less thermal lesion. In further embodiments,
other desired bioeffects can be induced based on the results
of the lesion characterization.
FIG. 5 is a block diagram illustrating a method 500 of
treating tissue at a target site in accordance with an embodi-
ment of the present technology. The method 500 can include
providing a pulsing protocol (block 502). As discussed
above, a pulsing protocol can take into account the ultra-
sound frequency at a HIFU source, peak positive pressure at
the focus, shock amplitude, pulse length, pulse repetition
frequency, and duty cycle. In other embodiments, additional
factors related to tissue boiling and shock wave heating can
be included in the pulsing protocol. In selected embodi-
ments, a derating process can be used to estimate values of
acoustic field parameters of the exposed tissue, and there-
from calculate the requisite peak positive pressures and
pulse lengths for shock wave heating and millisecond boil-
ing. The pulsing protocol can also be configured to minimize
thermal effects of the HIFU treatment on the tissue. For
example, as described above, the duty cycle can be less than
10% to ensure sufficient cooling occurs between shock wave
pulses and prevent thermal denature. As another example,
the pulse length can be less than approximately 100 ms such
that any thermally denatured volume formed within each
pulse is negligible. In a particular embodiment, atomization
can occur in liver tissue at 60 MPa with individual pulses
having a pulse duration of at least 20 µs. When the amplitude
is reduced to 15 MPa, atomization can occur when the pulse
duration is increased to 10 ms. The pressure threshold can be
even lower and reach diagnostic ultrasound levels for a
larger number of consecutive pulses or for tissues with less
structure. In a particular embodiment, blood clots can atom-
ize at 4 MPa in less than 70 µs and heparinize blood at 2 MPa
in less than 70 µs. In several embodiments, the time required
to achieve atomization is related to the shock wave ampli-
tude, wherein quicker atomization can correspond to higher
amplitudes, and vice versa. The pulsing protocol can be set
to take this and other treatment variable relationships into
account. Various other pulsing protocols can be established
to induce a desired type of lesion as described above.
Once the pulsing protocol is established, the method 500
can continue by positioning a focus of a HIFU source
proximate to a target site at a pressure-release interface
within tissue (block 504). The pressure-release interface can
be similar to the pressure-release interfaces described above
with reference to FIGS. 1-3C. For example, the pressure-
release interface can include an inherent or induced gas or
vapor cavity within tissue. The pressure-release interface
can be induced by any of the techniques described above,
such as laser ablation, vaporization droplets, injected lipo-
somes, cavitation clouds, etc.
The method 500 can further include delivering at lease
one pulse of ultrasound energy from the HIFU source to the
tissue (block 506) and generating shock waves in the tissue
to induce a lesion at the target site (block 508). In some
embodiments, each pulse of shock waves at the target site
can generate boiling bubbles within milliseconds. This rapid
millisecond boiling can mechanically disrupt the tissue
without evident thermal damage. Additionally, as described
above, the HIFU source can deliver shock waves to its focus
to consistently induce boiling within a localized treatment
area or can be planar to induce boiling over a larger area of
tissue. Therefore, the millisecond boiling provided by this
HIFU method 200 provides a repeatable, directable, and
predictable mechanical destruction of tissue to produce a
desired type of lesion. Alternatively, thermal treatment can
be applied. Optionally, the target site can be monitored
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during HIFU treatment to ensure boiling and/or otherwise
observe the effects of the HIFU treatment (block 210).
The method 500 can also include characterizing the lesion
based on a type or degree of mechanical or thermal ablation
at the target site (block 512). As described above, histologi- 5
cal and/or biochemical testing or observation can be per-
formed to distinguish or categorize among lesion types.
Based on the characterization, feedback can be sent to alter
or fine-tune the pulsing protocol to achieve a desired type of
lesion. 10
From the foregoing, it will be appreciated that specific
embodiments of the technology have been described herein
for purposes of illustration, but that various modifications
may be made without deviating from the disclosure. For
example, the HIFU system 100 of FIG. 1 can include 15
additional devices and/or systems to facilitate shock wave
heating of the tissue 108. For example, the HIFU system 100
can include a timing board to trigger the function generator
104, additional amplifiers 106, high-pass or other suitable
filters, a computer to drive the entire HIFU system 100, 20
and/or other suitable devices related to HIFU treatments.
Additional assays, stains, or alternate testing devices or
methods can be used to characterize lesions. Certain aspects
of the new technology described in the context of particular
embodiments may be combined or eliminated in other 25
embodiments. For example, the HIFU system 100 does not
need to include some of the devices shown in FIG. 1. In
selected embodiments, the HIFU system can include only
one of or a combination of the voltage probe 110, the PCD
124, the imaging system 114, and/or the high-speed camera 30
116 to monitor the thermal and mechanical effects of the
HIFU treatment. Additionally, while advantages associated
with certain embodiments of the new technology have been
described in the context of those embodiments, other
embodiments may also exhibit such advantages, and not all 35
embodiments need necessarily exhibit such advantages to
fall within the scope of the technology. Accordingly, the
disclosure and associated technology can encompass other
embodiments not expressly shown or described herein.
Thus, the disclosure is not limited except as by the appended 40
claims.
We claim:
1. A method of non-invasively treating tissue, the method
comprising:
pulsing ultrasound energy from an ultrasound source to a 45
target site in tissue, wherein the ultrasound source is
configured to emit high intensity focused ultrasound
(HIFU) waves, and wherein the target site comprises a
pressure-release interface located between tissue and a
gas or vapor cavity; 50
generating shock waves in the tissue to induce a lesion in
the tissue at the target site;
atomizing the tissue at the pressure-release interface to
create an acoustic fountain; and
characterizing the lesion based, at least in part, on a 55
degree of at least one of a mechanical or thermal
ablation of the tissue at the target site.
2. The method of claim 1 wherein characterizing the
lesion based on a degree of at least one of a mechanical or
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thermal ablation of the tissue comprises characterizing the
lesion based on a change of at least one of a cellular
structure, molecular structure, protein structure, protein
quantity, protein solubility, or cellular quantity at the target
site.
3. The method of claim 1 wherein characterizing the
lesion based on a degree of at least one of a mechanical or
thermal ablation of the lesion comprises using at least one of
a Haematoxylin and Eosin stain or a nicotinamide adenine
dinucleotide diaphorase stain to characterize the lesion.
4. The method of claim 1 wherein characterizing the
lesion based on a degree of at least one of a mechanical or
thermal ablation of the tissue comprises using at least one of
a serial salt extraction, protein-quantifying assay, or spec-
trophotometric determination to characterize the lesion.
5. The method of claim 1 wherein characterizing the
lesion based on a degree of at least one of a mechanical or
thermal ablation of the tissue comprises characterizing the
lesion as a liquid lesion, a paste lesion, a boiling lesion, or
a thermal lesion.
6. The method of claim 1 wherein the target site comprises
a naturally-occurring gas or vapor cavity located within the
tissue.
7. The method of claim 1, further comprising wetting the
pressure-release interface of the gas or vapor cavity located
within the tissue.
8. The method of claim 1 wherein generating shock waves
in the tissue comprises generating planar waves in the tissue.
9. The method of claim 1 wherein generating shock waves
in the tissue to induce a lesion in the tissue at the target site
comprises generating a focused beam of waves in the tissue
to create the acoustic fountain and atomize the tissue at the
target site.
10. The method of claim 1 wherein:
pulsing ultrasound energy comprises pulsing ultrasound
energy to the pressure-release interface at a pulse
length comprising multiple cycles of the ultrasound
wave; and
generating shock waves in the tissue comprises generating
shock waves having amplitudes between 10 MPa and
80 MPa.
11. The method of claim 1, further comprising selecting a
setting of the ultrasound source corresponding to a desired
mechanical or thermal phase of the lesion.
12. The method of claim 1, further comprising establish-
ing a pulsing protocol taking into account factors comprising
ultrasound frequency of the ultrasound source, pulse length,
pulse repetition frequency, and duty cycle.
13. The method of claim 1 wherein generating shock
waves in the tissue comprises generating shock waves such
that a surface of the tissue becomes concave.
14. The method of claim 1, further comprising creating
the pressure-release interface of the gas or vapor cavity
located within the tissue by introducing or inducing a gas or
vapor at the target site.
15. The method of claim 14 wherein inducing a gas or
vapor at the target site comprises inducing cavitation
bubbles or boiling bubbles in the tissue with HIFU.
